Cargando…
An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
BACKGROUND: With the emergence of molecularly targeted agents and immunotherapies, the landscape of phase I trials in oncology has been changed. Though these new therapeutic agents are very likely induce multiple low- or moderate-grade toxicities instead of DLT, most of the existing phase I trial de...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667395/ https://www.ncbi.nlm.nih.gov/pubmed/34895153 http://dx.doi.org/10.1186/s12874-021-01455-y |